Association of serum lactate and one-year mortality among women with coronary artery bypass grafting surgery: filling gaps in female Authors: Rong Zhang, Kai Zhang, Bo Li Published: 2026 ABSTRACT BackgroundAn abnormal perioperative blood lactate level has been reported to be associated with poor outcomes after cardiac surgery. However, their impact on female patients remains underexplored. This large-scale retrospective study evaluated the relationship between serum lactate level and one-year mortality in critically ill female patients with coronary artery bypass grafting.MethodsWe conducted a retrospective cohort analysis using data from an American ICU registry, focusing on female patients admitted for CABG at Beth Israel Deaconess Medical Center from 2008 to 2023. The primary outcome was one-year mortality. We employed Cox regression and a restricted cubic spline to examine the association between serum lactate and outcomes.ResultsA total of 1,279 female adult patients were included, with a mean age of 70.8 ± 10.0 years and a mean BMI of 30.8 ± 6.9 kg/m². After adjusting for confounders, Cox regression revealed that patients in the lowest quartile (Q1: <1.75 mmol/L) had a 0.96-fold increased risk of one-year mortality (HR 1.96; 95% CI 1.05–3.67, P = 0.036), while those in the third quartile (Q3: >2.3 mmol/L) had a 1.2-fold increased risk (HR 2.2; 95% CI 1.19–4.07, P = 0.012), compared to the second quartile (Q2: 1.75–2.3 mmol/L). Spline regression indicated a U-shaped dose-response relationship, with the lowest mortality risk observed at a serum lactate level of 140.5 mmol/L. Stratified and sensitivity analyses supported these findings.ConclusionsOur study suggests a U-shaped relationship between serum lactate levels and one-year mortality in female CABG patients.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13019-026-04188-5. Introduction Cardiovascular disease (CVD), particularly coronary artery disease (CAD), is a leading cause of morbidity and mortality worldwide [1]. According to clinical guidelines, coronary artery bypass grafting (CABG) remains the gold standard for treating multivessel coronary artery disease or diabetes mellitus, with left internal thoracic artery (LITA) to left anterior descending artery (LAD) grafting significantly improving long-term survival [1–3]. CABG is the most frequently performed cardiovascular surgery worldwide, accounting for 470,000 coronary bypass and valve procedures annually [4, 5]. The recent study by Spadafora et al. included 23,700 patients and found that female patients had poor prognosis one year after discharge from acute coronary syndrome (ACS), calling for more active management of women [10]. Therefore, it is essential to analyze women as an independent group to address their elevated mortality rates, improve prognoses, and identify specific risk factors, which necessitates the development of targeted treatment strategies [6]. Lactic acid serves as a marker for disease severity and therapeutic response [7]. It is produced from pyruvate, the end product of glycolysis, by lactate dehydrogenase (LDH) and is primarily generated in muscle tissue [8]. Under normal conditions, lactate is rapidly cleared by the liver and, to a lesser extent, the kidneys [9]. Elevated lactate levels can result from increased production, decreased clearance, or both. Prior studies have established lactate as a key biochemical marker for assessing tissue oxygenation, perfusion, and metabolic status in cardiovascular diseases [10, 11]. Abnormal lactate levels are associated with higher mortality in conditions such as heart failure [12, 13], myocardial infarction [14], and acute coronary syndrome [15]. In the context of cardiac surgery, elevated lactate levels are significant predictors of poor intraoperative and postoperative outcomes [16–18]. A study on extracorporeal circulation found that high lactate levels during surgery in CPB patients are mainly related to insufficient oxygen supply (type A high lactate levels) [19]. However, due to the fact that not all CABG patients use CPB, research on the effects of lactate on patients undergoing coronary artery bypass grafting is still limited. Only one study has linked blood lactate levels to postoperative acute kidney injury in CABG patients, without evaluating one-year outcomes [20]. Emerging evidence suggests that sex-specific differences in renal metabolism may further modulate lactate kinetics [21]. This body of evidence underscores the urgent need to delineate the specific relationship between serum lactate and prognosis within the female population, a group for which data remain disproportionately sparse. Additionally, high-quality research on specific risks, particularly in women, is lacking. Thus, this study aims to use a large national database to investigate the association between lactate levels and one-year mortality in women undergoing CABG. Method Study design and Ethics We conducted a retrospective cohort study using a deidentified patient-level databases of intensive care unit admissions. MIMIC-IV (3.0) database contains comprehensive and high-granularity information about well-defined and characterized patients admitted to ICUs at Beth Israel Deaconess Medical Center between 2008 and 2023 [22]. Our right to access the database and acquire the data were approved by the institutional review boards of the Massachusetts Institute of Technology (Cambridge, MA, USA) after one of our authors (KZ) finished the online training for the Collaborative Institutional Training Initiative (CITI) program of the National Institutes of Health (NIH) (Record ID 11639604) [21]. This study was conducted in accordance with the Helsinki Declaration of 1975. The Medical Information Mart for Intensive Care is publicly available after IRB approval by the Beth Israel Deaconess Medical Center in Boston, MA, USA (2001-P-001699/14) and the Massachusetts Institute of Technology, MA, USA (0403000206). Selection of participants Patients who meet the surgical indications for CABG underwent coronary artery bypass grafting (CABG) who met the standardized surgical treatment, with surgeries performed by a senior surgeon were eligible [23]. Male patients and patients with missing data on serum lactate level were excluded. For patients with multiple ICU admissions, only the first ICU stay was analyzed. Ultimately, 1,279 patients were included in the analysis (Fig. 1). Fig. 1Flowchart of the Study Cohort Selection Criteria Flowchart of the Study Cohort Selection Criteria Variable extraction The initial measurements taken within the first 24 h of ICU admission were used as the measurement parameters for this study. To extract patient information, Structured Query Language (SQL) and Navicat software (version 15) were utilized to retrieve the necessary data. Baseline characteristics within the first 24 h of ICU admission included demographic variables (age and body mass index), basic vital signs (arterial systolic and diastolic blood pressure, and temperature), blood biochemical markers (white blood cell count, red blood cell count, platelet count, sodium, potassium, total calcium, chloride, glucose, anion gap, fibrinogen, urea nitrogen, and creatinine), and clinical scores (Sequential Organ Failure Assessment [SOFA], Simplified Acute Physiology Score II [SAPS II], Acute Physiology and Chronic Health Evaluation III [APS III], Glasgow Coma Scale [GCS], and Charlson Comorbidity Index). Expose and outcome The primary exposure was early lactate measurement, defined as the initial lactate level recorded within 24 h postoperatively, a method demonstrated as effective in previous studies [24, 25]. Lactate levels were stratified into tertiles to balance clinical interpretability with statistical power, an approach previously validated in cardiovascular critical care literature for examining graded associations with adverse outcomes [26]. Patients were divided into three groups based on serum lactate tertiles: Q1 (< 1.75 mmol/L), Q2 (1.75–2.3 mmol/L), and Q3 (> 2.3 mmol/L). The primary outcome was one-year mortality at one year. Secondary outcomes included acute kidney injury (AKI) and sepsis. Statistical analyses Continuous variables were presented as mean ± standard deviation or median (interquartile range), as appropriate, while categorical variables were expressed as proportions. The Student’s t-test, analysis of variance, or the Mann-Whitney U test was applied as suitable for comparisons. Categorical variables were analyzed using the χ² test. Cox regression was used to model the association between early lactate measurement and mortality. Clinically relevant baseline variables and those supported by existing literature were included in the multivariate models. Model 1 had no adjustments. Model 2 adjusted for demographic variables (age and BMI). Model 3 incorporated vital signs (systolic and diastolic blood pressure, heart rate, and temperature) alongside Model 2. Model 4 further adjusted for blood biochemical markers (WBC, RBC, platelet count, sodium, potassium, calcium total, chloride, glucose, anion gap, fibrinogen, urea nitrogen, creatinine), Model 5 included comprehensive adjustments for SOFA score, APS III, SAPS II, GCS, and the Charlson Comorbidity Index. To address the information loss from categorizing serum lactate levels, restricted cubic splines were employed to assess the nonlinear relationship between serum lactate and one-year mortality. This method detects local data features and provides reliable estimates at data extremes, making it suitable for identifying marginal effects. The threshold effect of serum lactate on mortality was analyzed using piecewise regression models [27]. Kaplan-Meier survival analysis was employed to assess the incidence rate of endpoints among groups based on different levels of the lactate, and their differences were assessed through log-rank tests. Sensitivity analyses confirmed the robustness of findings. First, regression models assessed secondary endpoints (acute kidney injury and sepsis). Second, stratified analyses were performed to determine whether serum lactate effects varied across subgroups defined by age, BMI, SOFA, APS, SAPS, and Charlson scores, with multiplicative interactions assessed using the likelihood ratio test. Lastly, missing data were imputed via predictive mean matching using the Multivariate Imputation by Chained Equations (MICE) method in R, confirming stability across imputed datasets [28]. All statistical analyses were conducted in R (version 4.1.1) and Free Statistics software (version 1.8), with a two-sided p-value ≤ 0.05 considered statistically significant. The STROBE checklist was followed for reporting. Results Subject characteristics We analyzed 1,279 female patients who underwent CABG and were admitted to the ICU. The mean age of the cohort was 70.8 ± 10.0 years, and the mean BMI was 30.8 ± 6.9. Within one year, 103 patients (8.1%) died. Patients were stratified into tertiles based on serum lactate levels: Q1 (< 1.75 mmol/L), Q2 (1.75–2.3 mmol/L), and Q3 (> 2.3 mmol/L). Table 1 presents selected characteristics and hematologic data across these groups. Participants with serum lactate levels > 2.3 mmol/L were generally older and exhibited higher heart rate, white blood cell count, anion gap, SOFA score, APSIII score, and SAPSII score. Conversely, they had lower arterial blood pressure, platelet count, fibrinogen, urea nitrogen, and creatinine levels compared to those with lower lactate levels. Table 1Baseline Characteristics of ParticipantsVariablesTotal (n = 1279)Q1 (n = 419) bQ2 (n = 432) bQ3 (n = 428) bP value aAge, Mean ± SD70.8 ± 10.069.2 ± 10.571.2 ± 9.871.9 ± 9.7< 0.001BMI, Mean ± SD30.8 ± 6.931.0 ± 6.930.3 ± 6.431.2 ± 7.20.122Vital signsheart rate, Mean ± SD82.2 ± 9.081.3 ± 8.982.1 ± 9.083.1 ± 9.20.016ABPS, Mean ± SD112.6 ± 8.3113.8 ± 9.5112.5 ± 7.3111.5 ± 7.9< 0.001ABPD, Mean ± SD58.5 ± 99.756.2 ± 7.664.0 ± 171.355.2 ± 7.40.363temperature, Mean ± SD36.3 ± 3.336.3 ± 3.336.5 ± 1.836.1 ± 4.30.246Blood biochemical indicatorsWBC, Mean ± SD13.3 ± 4.812.5 ± 4.013.1 ± 4.414.4 ± 5.7< 0.001RBC, Mean ± SD3.2 ± 0.43.2 ± 0.43.2 ± 0.33.2 ± 0.40.87Platelet count, Mean ± SD171.5 ± 59.0179.4 ± 64.3173.3 ± 54.2161.8 ± 57.1< 0.001sodium, Mean ± SD138.1 ± 3.0138.0 ± 2.9138.0 ± 2.7138.3 ± 3.30.267potassium, Mean ± SD4.4 ± 0.44.3 ± 0.44.4 ± 0.44.4 ± 0.40.497Calcium total, Mean ± SD8.4 ± 0.68.4 ± 0.68.4 ± 0.68.4 ± 0.60.365chloride, Mean ± SD107.3 ± 3.8107.1 ± 4.0107.4 ± 3.8107.2 ± 3.70.642glucose, Mean ± SD125.1 ± 38.3122.7 ± 32.5124.0 ± 38.6128.5 ± 42.90.067anion gap, Mean ± SD11.5 ± 2.611.4 ± 2.711.3 ± 2.411.8 ± 2.70.007fibrinogen, Mean ± SD215.8 ± 71.7237.2 ± 81.3211.2 ± 63.3199.6 ± 64.2< 0.001Urea nitrogen, Mean ± SD17.4 ± 9.418.4 ± 11.016.8 ± 8.217.0 ± 8.70.022creatinine, Mean ± SD0.9 ± 0.91.0 ± 1.10.9 ± 0.70.9 ± 0.70.042clinical scoresofa, Mean ± SD5.0 ± 2.74.5 ± 2.54.7 ± 2.45.9 ± 2.9< 0.001APSⅢ, Mean ± SD39.4 ± 17.938.4 ± 16.837.9 ± 17.541.8 ± 19.20.002SAPSⅡ, Mean ± SD39.3 ± 11.337.9 ± 11.038.6 ± 10.741.2 ± 11.9< 0.001GCS, Mean ± SD13.4 ± 3.513.5 ± 3.413.5 ± 3.413.1 ± 3.80.23CHARLSON, Mean ± SD5.0 ± 2.24.9 ± 2.15.1 ± 2.15.1 ± 2.20.345outcomeOne-year mortality, n (%)0.002No1188 (92.9)386 (92.1)416 (96.3)386 (90.2)Yes91 ( 7.1)33 (7.9)16 (3.7)42 (9.8)AKI, n (%)0.641No315 (24.6)97 (23.2)112 (25.9)106 (24.8)Yes964 (75.4)322 (76.8)320 (74.1)322 (75.2)Sepsis, n (%)0.017No651 (50.9)236 (56.3)215 (49.8)200 (46.7)Yes628 (49.1)183 (43.7)217 (50.2)228 (53.3)%, weighted proportion.; BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressureWBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure AssessmentAPS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ : simplified acute physiology score Ⅱ, GCS, Glasgow Coma Scale;CHARLSON, Charlson comorbidity index, AKI: acute kidney injury, CRRT, Continuous Renal Replacement TherapyQ1(< 1.75 mmol/L), Q2(1.75–2.3 mmol/L) and Q3(>2.3 mmol/L)a P values of multiple comparisons were corrected by the False Discovery Rate methodb Q1-Q3: according to lactate Table 1Baseline Characteristics of ParticipantsVariablesTotal (n = 1279)Q1 (n = 419) bQ2 (n = 432) bQ3 (n = 428) bP value aAge, Mean ± SD70.8 ± 10.069.2 ± 10.571.2 ± 9.871.9 ± 9.7< 0.001BMI, Mean ± SD30.8 ± 6.931.0 ± 6.930.3 ± 6.431.2 ± 7.20.122Vital signsheart rate, Mean ± SD82.2 ± 9.081.3 ± 8.982.1 ± 9.083.1 ± 9.20.016ABPS, Mean ± SD112.6 ± 8.3113.8 ± 9.5112.5 ± 7.3111.5 ± 7.9< 0.001ABPD, Mean ± SD58.5 ± 99.756.2 ± 7.664.0 ± 171.355.2 ± 7.40.363temperature, Mean ± SD36.3 ± 3.336.3 ± 3.336.5 ± 1.836.1 ± 4.30.246Blood biochemical indicatorsWBC, Mean ± SD13.3 ± 4.812.5 ± 4.013.1 ± 4.414.4 ± 5.7< 0.001RBC, Mean ± SD3.2 ± 0.43.2 ± 0.43.2 ± 0.33.2 ± 0.40.87Platelet count, Mean ± SD171.5 ± 59.0179.4 ± 64.3173.3 ± 54.2161.8 ± 57.1< 0.001sodium, Mean ± SD138.1 ± 3.0138.0 ± 2.9138.0 ± 2.7138.3 ± 3.30.267potassium, Mean ± SD4.4 ± 0.44.3 ± 0.44.4 ± 0.44.4 ± 0.40.497Calcium total, Mean ± SD8.4 ± 0.68.4 ± 0.68.4 ± 0.68.4 ± 0.60.365chloride, Mean ± SD107.3 ± 3.8107.1 ± 4.0107.4 ± 3.8107.2 ± 3.70.642glucose, Mean ± SD125.1 ± 38.3122.7 ± 32.5124.0 ± 38.6128.5 ± 42.90.067anion gap, Mean ± SD11.5 ± 2.611.4 ± 2.711.3 ± 2.411.8 ± 2.70.007fibrinogen, Mean ± SD215.8 ± 71.7237.2 ± 81.3211.2 ± 63.3199.6 ± 64.2< 0.001Urea nitrogen, Mean ± SD17.4 ± 9.418.4 ± 11.016.8 ± 8.217.0 ± 8.70.022creatinine, Mean ± SD0.9 ± 0.91.0 ± 1.10.9 ± 0.70.9 ± 0.70.042clinical scoresofa, Mean ± SD5.0 ± 2.74.5 ± 2.54.7 ± 2.45.9 ± 2.9< 0.001APSⅢ, Mean ± SD39.4 ± 17.938.4 ± 16.837.9 ± 17.541.8 ± 19.20.002SAPSⅡ, Mean ± SD39.3 ± 11.337.9 ± 11.038.6 ± 10.741.2 ± 11.9< 0.001GCS, Mean ± SD13.4 ± 3.513.5 ± 3.413.5 ± 3.413.1 ± 3.80.23CHARLSON, Mean ± SD5.0 ± 2.24.9 ± 2.15.1 ± 2.15.1 ± 2.20.345outcomeOne-year mortality, n (%)0.002No1188 (92.9)386 (92.1)416 (96.3)386 (90.2)Yes91 ( 7.1)33 (7.9)16 (3.7)42 (9.8)AKI, n (%)0.641No315 (24.6)97 (23.2)112 (25.9)106 (24.8)Yes964 (75.4)322 (76.8)320 (74.1)322 (75.2)Sepsis, n (%)0.017No651 (50.9)236 (56.3)215 (49.8)200 (46.7)Yes628 (49.1)183 (43.7)217 (50.2)228 (53.3)%, weighted proportion.; BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressureWBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure AssessmentAPS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ : simplified acute physiology score Ⅱ, GCS, Glasgow Coma Scale;CHARLSON, Charlson comorbidity index, AKI: acute kidney injury, CRRT, Continuous Renal Replacement TherapyQ1(< 1.75 mmol/L), Q2(1.75–2.3 mmol/L) and Q3(>2.3 mmol/L)a P values of multiple comparisons were corrected by the False Discovery Rate methodb Q1-Q3: according to lactate Baseline Characteristics of Participants %, weighted proportion.; BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressure WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure Assessment APS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ : simplified acute physiology score Ⅱ, GCS, Glasgow Coma Scale; CHARLSON, Charlson comorbidity index, AKI: acute kidney injury, CRRT, Continuous Renal Replacement Therapy Q1(< 1.75 mmol/L), Q2(1.75–2.3 mmol/L) and Q3(>2.3 mmol/L) a P values of multiple comparisons were corrected by the False Discovery Rate method b Q1-Q3: according to lactate Serum lactate level and Mortality in in female patients with CABG To account for changes in serum lactate levels over time and examine short term serum lactate-mortality associations, serum lactate level and mortality associations were examined using Cox survival models as shown in Table 2. When serum lactate level was treated as a continuous variable each one unit increase in serum lactate increased the risk of one-year mortality by 59% (95% CI 1.27 ~ 2, p < 0.001). The exposure to serum lactate level was defined as a categorical variable with three groups, and the Q2 group was considered as the reference group throughout the analyses. After adjusting for confounding factors, both Q1 and Q3 were significantly associated with increased one-year mortality compared to Q2(Q1: HR 1.96; 95% CI 1.05 ~ 3.67, P = 0.036, Q3: HR 2.2; 95% CI 1.19 ~ 4.07, P = 0.012). Table 2Multivariable cox regression to assess the association of lactate with mortalityModel 1Model 2Model 3Model 4Model 5HR (95%CI)P valueHR (95%CI)P valueHR (95%CI)P valueHR (95%CI)P valueHR (95%CI)P valueOne-year mortalitycontinuous variable1.69 (1.48 ~ 1.94)< 0.0011.69 (1.47 ~ 1.94)< 0.0011.56 (1.32 ~ 1.84)< 0.0011.71 (1.42 ~ 2.05)< 0.0011.59 (1.27 ~ 2)< 0.001Categorical variableQ1(< 1.75)2.16 (1.19 ~ 3.92)0.0122.3 (1.27 ~ 4.19)0.0062.4 (1.31 ~ 4.37)0.0041.69 (0.9 ~ 3.18)0.1021.96 (1.05 ~ 3.67)0.036Q2(1.75–2.3)1(Ref)1(Ref)1(Ref)1(Ref)1(Ref)Q3(>2.3)2.77 (1.56 ~ 4.92)0.0012.74 (1.54 ~ 4.88)0.0012.42 (1.35 ~ 4.33)0.0032.55 (1.41 ~ 4.61)0.0022.2 (1.19 ~ 4.07)0.012P for tread0.2320.3620.8110.0960.647Abbreviations: the unit of lactate is mmol/L, BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressure,WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure AssessmentAPS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ: simplified acute physiology score ii, GCS, Glasgow Coma Scale;CHARLSON, Charlson comorbidity index, AKI: acute kidney injury, CRRT, Continuous Renal Replacement TherapyCI: confidence interval; HR: hazard ratio, Ref: referenceModel 1: No adjustmentModel 2: Adjusted for demographic variables(age, BMI )Model 3: Adjusted for demographic variables, Basic vital signs(heart rate, ABPS, ABPD, Temperature)Model 4: Adjusted for demographic variables, Basic vital signs, Blood biochemical indicators(WBC, RBC, platelet count, sodium, potassium, calcium total, chloride, glucose, anion gap, fibrinogen, urea nitrogen, creatinine, )Model 5: Adjusted for demographic variables, Basic vital signs, Blood biochemical indicators, SOFA, APS Ⅲ, SAPSⅡ, GCS, CHARLSON Table 2Multivariable cox regression to assess the association of lactate with mortalityModel 1Model 2Model 3Model 4Model 5HR (95%CI)P valueHR (95%CI)P valueHR (95%CI)P valueHR (95%CI)P valueHR (95%CI)P valueOne-year mortalitycontinuous variable1.69 (1.48 ~ 1.94)< 0.0011.69 (1.47 ~ 1.94)< 0.0011.56 (1.32 ~ 1.84)< 0.0011.71 (1.42 ~ 2.05)< 0.0011.59 (1.27 ~ 2)< 0.001Categorical variableQ1(< 1.75)2.16 (1.19 ~ 3.92)0.0122.3 (1.27 ~ 4.19)0.0062.4 (1.31 ~ 4.37)0.0041.69 (0.9 ~ 3.18)0.1021.96 (1.05 ~ 3.67)0.036Q2(1.75–2.3)1(Ref)1(Ref)1(Ref)1(Ref)1(Ref)Q3(>2.3)2.77 (1.56 ~ 4.92)0.0012.74 (1.54 ~ 4.88)0.0012.42 (1.35 ~ 4.33)0.0032.55 (1.41 ~ 4.61)0.0022.2 (1.19 ~ 4.07)0.012P for tread0.2320.3620.8110.0960.647Abbreviations: the unit of lactate is mmol/L, BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressure,WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure AssessmentAPS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ: simplified acute physiology score ii, GCS, Glasgow Coma Scale;CHARLSON, Charlson comorbidity index, AKI: acute kidney injury, CRRT, Continuous Renal Replacement TherapyCI: confidence interval; HR: hazard ratio, Ref: referenceModel 1: No adjustmentModel 2: Adjusted for demographic variables(age, BMI )Model 3: Adjusted for demographic variables, Basic vital signs(heart rate, ABPS, ABPD, Temperature)Model 4: Adjusted for demographic variables, Basic vital signs, Blood biochemical indicators(WBC, RBC, platelet count, sodium, potassium, calcium total, chloride, glucose, anion gap, fibrinogen, urea nitrogen, creatinine, )Model 5: Adjusted for demographic variables, Basic vital signs, Blood biochemical indicators, SOFA, APS Ⅲ, SAPSⅡ, GCS, CHARLSON Multivariable cox regression to assess the association of lactate with mortality Abbreviations: the unit of lactate is mmol/L, BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressure, WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure Assessment APS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ: simplified acute physiology score ii, GCS, Glasgow Coma Scale; CHARLSON, Charlson comorbidity index, AKI: acute kidney injury, CRRT, Continuous Renal Replacement Therapy CI: confidence interval; HR: hazard ratio, Ref: reference Model 1: No adjustment Model 2: Adjusted for demographic variables(age, BMI ) Model 3: Adjusted for demographic variables, Basic vital signs(heart rate, ABPS, ABPD, Temperature) Model 4: Adjusted for demographic variables, Basic vital signs, Blood biochemical indicators(WBC, RBC, platelet count, sodium, potassium, calcium total, chloride, glucose, anion gap, fibrinogen, urea nitrogen, creatinine, ) Model 5: Adjusted for demographic variables, Basic vital signs, Blood biochemical indicators, SOFA, APS Ⅲ, SAPSⅡ, GCS, CHARLSON Dose–response relationships Figure 2 illustrates the non-linear relationship between serum lactate levels and mortality in hospitalized patients, analyzed using restricted cubic splines. The cubic spline analysis revealed a U-shaped curve for mortality, with the lowest risk occurring at a lactate level of 2.447 mmol/L (Table 3). Levels exceeding this threshold were associated with a non-linear increase in mortality risk. Specifically, below 2.447 mmol/L, serum lactate levels were inversely related to mortality (HR 0.347, 95% CI 0.159–0.757, P = 0.0078). In contrast, levels above 2.447 mmol/L correlated with an increased mortality risk (HR 1.904, 95% CI 1.265–2.864, P = 0.002). Figure 3 depicts the Kaplan–Meier curves during the follow-up survival curve according to the occurrence of mortality for three lactate groups. The incidence of death with a high lactate index was significantly higher (p = 0.0016) among female patients with CABG. Fig. 2Dose–Response Relationships between lactate with one-year mortality rate Solid and dashed lines represent the predicted value and 95% confidence intervals. Adjusted for demographic variables(age, BMI)༌Basic vital signs (heart rate, ABPS༌ABPD, Temperature)༌Blood biochemical indicators (WBC, RBC༌platelet count, sodium, potassium, calcium total, chloride, glucose, anion gap, fibrinogen, urea nitrogen, creatinine, ) SOFA༌APS Ⅲ, SAPSⅡ, GCS, CHARLSON. Abbreviations: the unit of lactate is mmol/L, BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressure, WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure Assessment APS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ: simplified acute physiology score ii, GCS, Glasgow Coma Scale; CHARLSON, Charlson comorbidity index༌AKI༚acute kidney injury༌CRRT, Continuous Renal Replacement Therapy CI: confidence interval; HR༚hazard ratio༌Ref: reference Dose–Response Relationships between lactate with one-year mortality rate Solid and dashed lines represent the predicted value and 95% confidence intervals. Adjusted for demographic variables(age, BMI)༌Basic vital signs (heart rate, ABPS༌ABPD, Temperature)༌Blood biochemical indicators (WBC, RBC༌platelet count, sodium, potassium, calcium total, chloride, glucose, anion gap, fibrinogen, urea nitrogen, creatinine, ) SOFA༌APS Ⅲ, SAPSⅡ, GCS, CHARLSON. Abbreviations: the unit of lactate is mmol/L, BMI: body mass index; ABPS: Arterial systolic pressure; ABPD: Arterial diastolic pressure, WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure Assessment APS Ⅲ: Acute Physiology and Chronic Health Evaluation Ⅲ; SAPSⅡ: simplified acute physiology score ii, GCS, Glasgow Coma Scale; CHARLSON, Charlson comorbidity index༌AKI༚acute kidney injury༌CRRT, Continuous Renal Replacement Therapy CI: confidence interval; HR༚hazard ratio༌Ref: reference Table 3Threshold effect analysis of relationship of lactate with one year mortality rateMortality rateAdjusted HR_95CIP valueTwo modellactate ≤ 2.4470.347 (0.159,0.757)0.0078lactate ≥ 2.4471.904 (1.265,2.864)0.002Likelihood Ratio test-< 0.001Non-linear Test*1-0.027Non-linear Test*2-< 0.001Adjusted for demographic variables (age, BMI), Basic vital signs (heart rate, Abps, Abpd, Temperature), Blood biochemical indicators (wbc, rbc, plateletcount, sodium, potassium, calciumtotal, chloride, glucose, anion gap, fibrinogen, ureanitrogen, creatinine, ), SOFA, apsiii, sapsii, gcs, charlsonAbbreviations: the unit of lactate is mmol/L, BMI: body mass index; Abps: Arterial systolic pressure; Abpd: Arterial diastolic pressure,WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure AssessmentApsⅢ: Acute Physiology and Chronic Health Evaluation Ⅲ; sapsii : simplified acute physiology score ii, GCS, Glasgow Coma Scale;Charlson, Charlson comorbidity index, aki: acute kidney injury, crrt, Continuous Renal Replacement TherapyCI: confidence interval; OR: odds ratios, Ref: reference Table 3Threshold effect analysis of relationship of lactate with one year mortality rateMortality rateAdjusted HR_95CIP valueTwo modellactate ≤ 2.4470.347 (0.159,0.757)0.0078lactate ≥ 2.4471.904 (1.265,2.864)0.002Likelihood Ratio test-< 0.001Non-linear Test*1-0.027Non-linear Test*2-< 0.001Adjusted for demographic variables (age, BMI), Basic vital signs (heart rate, Abps, Abpd, Temperature), Blood biochemical indicators (wbc, rbc, plateletcount, sodium, potassium, calciumtotal, chloride, glucose, anion gap, fibrinogen, ureanitrogen, creatinine, ), SOFA, apsiii, sapsii, gcs, charlsonAbbreviations: the unit of lactate is mmol/L, BMI: body mass index; Abps: Arterial systolic pressure; Abpd: Arterial diastolic pressure,WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure AssessmentApsⅢ: Acute Physiology and Chronic Health Evaluation Ⅲ; sapsii : simplified acute physiology score ii, GCS, Glasgow Coma Scale;Charlson, Charlson comorbidity index, aki: acute kidney injury, crrt, Continuous Renal Replacement TherapyCI: confidence interval; OR: odds ratios, Ref: reference Threshold effect analysis of relationship of lactate with one year mortality rate Adjusted for demographic variables (age, BMI), Basic vital signs (heart rate, Abps, Abpd, Temperature), Blood biochemical indicators (wbc, rbc, plateletcount, sodium, potassium, calciumtotal, chloride, glucose, anion gap, fibrinogen, ureanitrogen, creatinine, ), SOFA, apsiii, sapsii, gcs, charlson Abbreviations: the unit of lactate is mmol/L, BMI: body mass index; Abps: Arterial systolic pressure; Abpd: Arterial diastolic pressure, WBC, white blood cell count; RBC, red blood cell count; sofa, Sequential Organ Failure Assessment ApsⅢ: Acute Physiology and Chronic Health Evaluation Ⅲ; sapsii : simplified acute physiology score ii, GCS, Glasgow Coma Scale; Charlson, Charlson comorbidity index, aki: acute kidney injury, crrt, Continuous Renal Replacement Therapy CI: confidence interval; OR: odds ratios, Ref: reference Fig. 3The Kaplan–Meier survival analysis for functions The Kaplan–Meier survival analysis for functions Sensitivity analysis Several sensitivity analyses were performed to evaluate the robustness of our findings. First, we assessed the relationship between serum lactate levels and sepsis and acute kidney injury (AKI). After adjusting for confounders, serum lactate levels were associated with a decreased risk of AKI (HR 0.8, 95% CI 0.66–0.98, P = 0.031; see Supplementary Table 1). Second, we conducted subgroup analyses to explore interactions based on age, BMI, SOFA score, APS, SAPS, and Charlson comorbidity index (Figs. 4). We evaluated all such interactions in our analyses and found only one such effect. Lastly, we employed multiple imputation to address missing data, and logistic regression analyses on the imputed datasets confirmed the stability of our results (see Supplementary Table 2). Fig. 4Stratified analysis of the association of association of serum lactate with one-year mortality. Adjusted HRs are shown. Interaction was tested adjusted. Subgroups with and adjusted P-interaction < 0.05 were considered effect modifiers on the association of serum lactate with one-year mortality Stratified analysis of the association of association of serum lactate with one-year mortality. Adjusted HRs are shown. Interaction was tested adjusted. Subgroups with and adjusted P-interaction < 0.05 were considered effect modifiers on the association of serum lactate with one-year mortality Discussion In our study of a large cohort of female ICU patients undergoing surgical revascularization, we identified a significant association between lactate levels and patient outcomes. Cox regression analysis revealed that both low and high lactate levels are risk factors for one-year mortality. We further validated these findings using restricted cubic spline (RCS) analysis, which demonstrated a U-shaped relationship with mortality, with the point at a lactate level of 2.447 mmol/L. Additionally, subgroup and sensitivity analyses confirmed the reliability and robustness of our results. Recent research has highlighted significant gender disparities in outcomes following coronary artery bypass grafting (CABG). Numerous studies indicate that women experience poorer prognoses after CABG compared to men [29, 30]. This difference is attributed to the distinct pathophysiology of ischemic heart disease in women [31, 32]. It is essential to treat women as a separate group and to investigate the determinants of operative outcomes specific to this population [6, 33, 34]. Serum lactate levels have emerged as a common predictor of adverse outcomes following cardiovascular surgery, as demonstrated in studies involving pediatric congenital heart disease [35–37]. Given that CABG is the most frequently performed cardiac surgery, its outcomes are likely influenced by blood lactate levels in female patients. However, there is a notable lack of data in this area, which our research aims to address. To our knowledge, our study is the first to establish a link between serum lactate levels and one-year mortality in female CABG patients. Furthermore, our findings underscore the clinical significance of monitoring early serum lactate levels post-surgery in the management of female patients. Previous studies have examined the relationship between lactate levels and outcomes, primarily identifying an association between blood lactate and postoperative acute kidney injury without investigating one-year outcomes [20]. Our study focuses on one-year outcomes and employs restricted cubic spline (RCS) functions for dose-response analysis. We found a U-shaped association between serum lactate concentrations and hazard ratios (HRs) for all-cause mortality, indicating that both high and low lactate levels correlate with an increased mortality risk. The Cox model determined that a lactate level of 2.447 mmol/L corresponds to the lowest mortality risk; below this threshold, mortality risk decreases with rising lactate, while above it, risk increases. Given the annual rise in cardiac surgeries, including coronary artery bypass grafting (CABG), individualized and timely risk assessment is essential for optimizing treatment strategies and resource allocation [38]. Several studies have evaluated prognostic markers such as triglyceride-glucose index [39], Preoperative frailty [40], prognostic nutritional index [41] and Inflammatory prognostic index [42]. However, these markers are often costly, time-consuming, and insensitive to outcomes. In contrast, serum lactate is a cost-effective and rapid measurement commonly used in clinical practice. Our findings suggest that serum lactate concentration can serve as a rapid risk assessment tool for critically ill female patients undergoing coronary artery bypass grafting (CABG). Positioning serum lactate as a useful prognostic marker for critically ill female CABG patients. The U-shaped relationship identified in our restricted cubic spline analysis, wherein both the lowest and highest lactate tertiles were associated with increased 1-year mortality compared to the intermediate reference range, merits careful pathophysiological consideration. The elevated hazard observed with hyperlactatemia (the uppermost tertile) aligns with the well-characterized paradigm of type A and type B lactic acidosis in the perioperative setting, reflecting tissue hypoperfusion, occult cardiogenic shock, or persistent systemic inflammatory response following cardiopulmonary bypass. Conversely, the paradoxical increase in mortality risk among women with the lowest lactate concentrations may be attributable to a reduced capacity for lactate production—a marker of diminished physiological reserve—in patients with pre-existing frailty, malnutrition, or severe hepatic dysfunction. In such individuals, an ostensibly “normal” or low lactate value may obscure underlying circulatory insufficiency due to substrate depletion or impaired hepatic gluconeogenesis, conditions that are not infrequent in the predominantly older female cohort undergoing CABG in this study. Nevertheless, several limitations warrant acknowledgment. First, the observational nature of the MIMIC-IV database precludes definitive causal inference, and residual confounding by unmeasured variables—including the precise timing of lactate measurement relative to hemodynamic interventions, nutritional status, or subclinical hepatic impairment—cannot be entirely excluded. Second, and importantly, the study cohort was derived exclusively from a single tertiary care center in North America and was intentionally restricted to women undergoing CABG. Consequently, the generalizability of our findings to other geographic populations, healthcare settings with different perioperative management protocols, or male patients undergoing CABG may be limited. The U-shaped lactate-mortality relationship observed in this female cohort may not be directly extrapolated to male populations, in whom baseline metabolic profiles and post-CABG outcomes have been shown to differ. Future prospective, multicenter studies incorporating serial lactate monitoring and including both sexes are warranted to validate and extend these observations across broader surgical populations. The relationship between appropriate early postoperative blood lactate levels and mortality risk is likely mediated by several mechanisms, despite limited understanding of the underlying pathways. Firstly, plasma free fatty acids (FFAs), which are significant contributors to atherosclerosis, predominantly result from triglyceride breakdown in adipose tissue. Optimal lactate levels activate GPR81, leading to the suppression of lipolysis through insulin-mediated antilipolytic effects in adipocytes, including those from mice, rats, humans, and differentiated 3T3-L1 cells [43–45]. GPR81-selective agonists can effectively inhibit lipolysis and FFA production in vitro and in animal models without adverse effects [46]. Secondly, areas of the vasculature subjected to oscillatory shear stress (OSS) are at a higher risk of developing atherosclerotic lesions [47, 48]. Physiologically relevant doses of optimal lactate can mitigate OSS-induced declines in GPR81 expression, and GPR81 activation can provide protective benefits to endothelial cells exposed to OSS [49]. Thirdly, the proliferation of smooth muscle cells (SMCs) is a crucial factor in the development of atherosclerosis [50]. MCT3 mRNA and protein levels are associated with the severity of atherosclerosis, and impaired transport of optimal lactate due to MCT3 inhibition may lead to enhanced SMC proliferation, exacerbating atherosclerotic processes. Optimal lactate also has anti-atherosclerotic properties, which may help explain the protective effects of moderate exercise against coronary heart disease. The strengths of this study include a large sample size, a specific focus on female patients, one-year follow-up, and robust statistical analysis. To our knowledge, it provides the most comprehensive data on appropriate early postoperative blood lactate levels for women undergoing coronary artery bypass grafting (CABG), thereby enhancing the current understanding of management strategies for this population. However, several limitations must be acknowledged. First, as a retrospective cohort study, it does not allow for causal inferences. There are still some unmeasured confounding factors due to the characteristics of retrospective studies and the database situation. Second, our cohort is representative of a typical American female population, which may limit the generalizability of the findings to other demographics and male patients. Thirdly, the use of lactate values in the first 24 h may not capture dynamic changes in the late postoperative period. Finally, existing research indicates potential outcome differences between extracorporeal and non-extracorporeal circulation, highlighting the need for future subgroup analyses, especially among patients undergoing non-extracorporeal CABG [51]. Future research also requires forward-looking and multi‐institutional datasets. Conclusions In conclusion, Our study suggests a U-shaped relationship between serum lactate levels and mortality, with both low and high lactate levels associated with increased overall mortality in female patients undergoing coronary artery bypass grafting (CABG). In clinical practice, all healthcare professionals should promptly pay attention to the serum lactate levels of female CABG patients. More research is needed in the future to fully understand these effects. Electronic Supplementary Material Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2